Who Exports Losartan from India — 506 Suppliers Behind a $301.0M Market
India's losartan export market is supplied by 506 active exporters who collectively shipped $301.0M across 10,898 shipments. ZYDUS LIFESCIENCES LIMITED leads with a 24.1% market share, followed by MICRO LABS LIMITED and CIPLA LIMITED. The top 5 suppliers together control 44.6% of total export value, reflecting a moderately competitive market structure.
Top Losartan Exporters from India — Ranked by Export Value
ZYDUS LIFESCIENCES LIMITED is the leading losartan exporter from India, holding a 24.1% share of the $301.0M market across 10,898 shipments from 506 exporters. The top 5 suppliers — ZYDUS LIFESCIENCES LIMITED, MICRO LABS LIMITED, CIPLA LIMITED, AUROBINDO PHARMA LTD, ALEMBIC PHARMACEUTICALS LIMITED — collectively control 44.6% of total export value, indicating a competitive market. Individual shares are: ZYDUS LIFESCIENCES LIMITED (24.1%), MICRO LABS LIMITED (6.8%), CIPLA LIMITED (5.2%), AUROBINDO PHARMA LTD (4.3%), ALEMBIC PHARMACEUTICALS LIMITED (4.2%).
Top Losartan Exporters from India
Ranked by export value · 506 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | ZYDUS LIFESCIENCES LIMITED ZAART 50 TABLETS .LOSARTAN POTASSIUM TABLETS 100MGLOSARTAN POTASSIUM TABLETS 50MG | $72.5M | 15 | 24.1% |
| 2 | MICRO LABS LIMITED ZAART 50 TABLETS .PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE-SAPHLOR-50PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLOR 50 | $20.5M | 26 | 6.8% |
| 3 | CIPLA LIMITED ZAART 50 TABLETS .ZAART 50 TABLETS [1296X10X10'S]AMLOZAAR ( (LOSARTAN POTASSIUM + AMLODIP | $15.6M | 3 | 5.2% |
| 4 | AUROBINDO PHARMA LTD LOSARTAN POTASSIUM TABLETS 100MGLOSARTAN POTASSIUM TABLETS 50MGLOSARTAN POTASSIUM 100 MG 1X90T | $13.0M | 11 | 4.3% |
| 5 | ALEMBIC PHARMACEUTICALS LIMITED LOSARTAN POTASSIUM TABLETS 100MGLOSARTAN POTASSIUM TABLETS 50MGLOSARTAN POTASSIUM 100 MG 1X90T | $12.6M | 2 | 4.2% |
| 6 | LUPIN LIMITED LOSARTAN POTASSIUM TABLETS 100MGLOSARTAN POTASSIUM TABLETS 50MGLOSARTAN POTASSIUM 100 MG 1X90T | $12.5M | 2 | 4.2% |
| 7 | AJANTA PHARMA LIMITED PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE-SAPHLOR-50PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLOR 50PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLOR-100 | $10.6M | 2 | 3.5% |
| 8 | EMIL PHARMACEUTICAL INDUSTRIES PVT LTD LOSARTAN TAB 50MG ASCEND CHILELOSARTAN 50MGX1200 COMP BE.: PO 10263 LO | $9.5M | 2 | 3.2% |
| 9 | IPCA LABORATORIES LIMITED ZAART 50 TABLETS .PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE-SAPHLOR-50PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLOR 50 | $9.5M | 19 | 3.2% |
| 10 | APL HEALTHCARE LIMITED LOSARTAN POTASSIUM TABLETS 100MGLOSARTAN POTASSIUM TABLETS 50MGLOSARTAN POTASSIUM 100 MG 1X90T | $7.5M | 1 | 2.5% |
| 11 | CAPLIN POINT LABORATORIES LIMITED LOSARTAN TAB 50MG ASCEND CHILELOSARTAN 50MGX1200 COMP BE.: PO 10263 LO | $7.5M | 8 | 2.5% |
| 12 | MSN LABORATORIES PRIVATE LIMITED LOSARTAN POTASSIUM TABLETS 100MGLOSARTAN POTASSIUM TABLETS 50MGLOSARTAN POTASSIUM 100 MG 1X90T | $7.4M | 1 | 2.5% |
| 13 | CADILA HEALTHCARE LIMITED ZAART 50 TABLETS .LOSARTAN POTASSIUM TABLETS 100MGLOSARTAN POTASSIUM TABLETS 50MG | $5.6M | 11 | 1.9% |
| 14 | AUROBINDO PHARMA LIMITED LOSARTAN POTASSIUM TABLETS 100MGLOSARTAN POTASSIUM TABLETS 50MGLOSARTAN POTASSIUM 100 MG 1X90T | $5.1M | 5 | 1.7% |
| 15 | UNICHEM LABORATORIES LIMITED LOSARTAN POTASSIUM TABLETS 100MGLOSARTAN POTASSIUM TABLETS 50MGLOSARTAN POTASSIUM 100 MG 1X90T | $5.1M | 6 | 1.7% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Losartan exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Zydus Lifesciences Limited | Warning Letter (August 20 | Unknown | Unknown | Unknown | Received FDA warning letter for cGMP violations at Jarod facility. |
| Cipla Limited | Warning Letter (November | Unknown | Unknown | Unknown | FDA cited significant cGMP violations at Indore facility. |
| Aurobindo Pharma Limited | Warning Letter (June 2019 | Unknown | Unknown | Unknown | FDA identified cGMP violations at Unit IV facility. |
| Lupin Limited | Warning Letter (November | Unknown | Unknown | Unknown | Received FDA warning letter highlighting quality concerns. |
| Cadila Healthcare Limited | Warning Letter (December | Unknown | Unknown | Unknown | FDA cited data integrity issues at Zyfine and Moraiya facilities. |
TransData Nexus reviewed the regulatory standing of 5 leading Losartan exporters from India. 0 hold US FDA facility approvals, 0 maintain WHO-GMP certification, and 0 are EU GMP compliant. 5 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Losartan sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as India's "Bulk Drug Capital," plays a pivotal role in the production of active pharmaceutical ingredients (APIs), including Losartan. The city's industrial zones, such as Bollaram and Pashamylaram, host numerous API manufacturing facilities. For instance, Medchem Labs, located in Bollaram, specializes in Losartan Potassium production. (mytat.co) The presence of Genome Valley, a hub for R&D and biologics, further strengthens Hyderabad's position in the pharmaceutical sector.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its expertise in pharmaceutical formulations. Companies like Torrent Pharmaceuticals, headquartered in Ahmedabad, have a significant presence in this region. Torrent operates multiple manufacturing plants, including those in Dahej and Indrad, Gujarat, contributing to the production and export of Losartan formulations. The region's well-established infrastructure and skilled workforce make it a key player in the formulation segment.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products, including Losartan. Mumbai's strategic location and port facilities facilitate efficient international distribution. Companies like Lupin Limited, headquartered in Mumbai, leverage this advantage to export Losartan to various global markets. The region's proximity to major ports ensures timely and cost-effective shipping, enhancing India's pharmaceutical export capabilities.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi and Nalagarh in Himachal Pradesh have emerged as significant pharmaceutical manufacturing zones, initially attracting companies through tax incentives. While some of these incentives have phased out, the region continues to host numerous formulation units due to its established ecosystem. Companies benefit from the area's manufacturing lineage, trained workforce, and mature vendor base for packaging materials.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and compliance records of suppliers, especially those in Hyderabad and Ahmedabad-Vadodara, to ensure consistent quality and supply.
- Leverage Export Hubs: Utilize the Mumbai-Thane-Raigad region's export infrastructure for efficient international distribution of Losartan products.
- Monitor Regulatory Compliance: Stay updated on regulatory changes and compliance requirements in key manufacturing zones to maintain uninterrupted supply chains.
By strategically sourcing from these diverse pharmaceutical clusters, companies can enhance the resilience and efficiency of their Losartan supply chains.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Losartan exporters from India
Zydus Lifesciences Limited — Zydus acquires Agenus' CDMO business
In June 2025, Zydus Lifesciences Limited acquired the contract development and manufacturing organization (CDMO) business of Agenus, including two biologics manufacturing sites in Emeryville and Berkeley. This acquisition aims to enhance Zydus' biologics manufacturing capabilities. - IMPACT: This acquisition is expected to bolster Zydus' production capacity, potentially increasing Losartan exports.
Impact: This acquisition is expected to bolster Zydus' production capacity, potentially increasing Losartan exports.
Alembic Pharmaceuticals Limited — Alembic partners with Amlan for poultry health solutions
In March 2025, Alembic Pharmaceuticals entered into a strategic agreement with Amlan International to distribute mineral-based feed additives for poultry health in India. This partnership aims to expand Alembic's presence in the animal health sector. - IMPACT: While this collaboration focuses on animal health, it may indirectly affect Alembic's resource allocation, potentially influencing Losartan production and exports.
Impact: While this collaboration focuses on animal health, it may indirectly affect Alembic's resource allocation, potentially influencing Losartan production and exports.
Alembic Pharmaceuticals Limited — Alembic receives USFDA approval for Tretinoin Cream
In August 2025, Alembic Pharmaceuticals obtained final approval from the USFDA for Tretinoin Cream USP 0.025%, a generic version of Retin-A, used for treating acne vulgaris. This approval expands Alembic's dermatology product portfolio in the U.S. market. - IMPACT: The approval may enhance Alembic's revenue streams, potentially supporting increased Losartan export activities.
Impact: The approval may enhance Alembic's revenue streams, potentially supporting increased Losartan export activities.
Common Questions — Losartan Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which losartan supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, ZYDUS LIFESCIENCES LIMITED leads with 562 recorded shipments worth $72.5M. MICRO LABS LIMITED (676 shipments) and CIPLA LIMITED (184 shipments) are also established high-volume exporters.
Q How many losartan manufacturers are there in India?
India has 506 active losartan exporters with a combined export market of $301.0M across 10,898 shipments to 141 countries. The top 5 suppliers hold 44.6% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for losartan from India?
Average FOB unit price: $9.35 per unit, ranging from $0.00 to $3734.85. Average shipment value: $27.6K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 506 verified Indian exporters of Losartan ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 10,898 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 141 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
10,898 Verified Shipments
506 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists